The anastrozole, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial in post-menopausal women: Regional variations in surgical practice in patients recruited into the trial. The ATAC Trialists' Group.

被引：0

作者：

Sainsbury, R ^{[1
]}

机构：

[1] Huddersfield Royal Infirm, Huddersfield, W Yorkshire, England

来源：

ANNALS OF ONCOLOGY | 2000年 / 11卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

78P

引用

页码：20 / 20

页数：1

共 38 条

[21] Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial
Duffy, SRG
Taylor, L
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (06) : 1921 - 1927
[22] The ATAC ('Arimidex', Tamoxifen, alone or in combination) early breast cancer trial in postmenopausal patients: endometrial sub-protocol results
Duffy, S
Jackson, T
INTERNATIONAL JOURNAL OF CANCER, 2002, : 137 - 138
[23] The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment
Duffy, S
Jackson, TL
Lansdown, M
Philips, K
Wells, M
Pollard, S
Clack, G
Coibion, M
Bianco, AR
HUMAN REPRODUCTION, 2006, 21 (02) : 545 - 553
[24] Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial
Mansel, R.
Locker, G.
Fallowfield, L.
Benedict, A.
Jones, D.
BRITISH JOURNAL OF CANCER, 2007, 97 (02) : 152 - 161
[25] Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial
R Mansel
G Locker
L Fallowfield
Á Benedict
D Jones
British Journal of Cancer, 2007, 97 : 152 - 161
[26] Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the Arimidex (A), Tamoxifen (T), Alone or in Combination (ATAC) Trial.
Cella, D
Fallowfield, L
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 23S - 23S
[27] Cost-utility analysis of anastrozole vs tamoxifen in postmenopausal women with early breast cancer from a UK national health service perspective: The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Mansel, RE
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 41S - 41S
[28] Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy for postmenopausal women with early hormone-receptor positive breast cancer - an evaluation of the ATAC-trial.
Lundkvist, J.
Paulsson, T.
Borgstrom, F.
Kasteng, F.
Sobocki, P.
Lidgren, M.
Henriksson, R.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S229 - S229
[29] TAMOXIFEN PLUS SEQUENTIAL CMF CHEMOTHERAPY VERSUS TAMOXIFEN ALONE IN POST-MENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER - RANDOMIZED TRIAL
GLICK, JH
CREECH, RH
TORRI, S
HOLROYDE, C
BRODOVSKY, H
CATALANO, RB
VARANO, M
CANCER, 1980, 45 (04) : 735 - 741
[30] The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy
Duffy, S
Jackson, TL
Lansdown, M
Philips, K
Wells, M
Pollard, S
Clack, G
Coibion, M
Bianco, AR
HUMAN REPRODUCTION, 2005, 20 (01) : 294 - 301

← 1 2 3 4 →